Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant palbociclib + letrozole for HR-positive/HER2-negative intermediate-risk localized breast cancer
2019-004899-19Phase 2Completed
- Sponsor
- Unicancer
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of palbociclib and letrozole in breast cancer, sponsored by Unicancer. Primary endpoint: Invasive disease-free survival. Started Apr 2020; status: completed.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-004899-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004899-19.